Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug
Just as Noctiva obtains FDA approval as the first drug for nocturia due to nocturnal polyuria, Allergan bails on collaboration signed seven years ago.
You may also be interested in...
Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options
North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Company plans to meet with caregivers and consider other options before moving forward.